KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Sales and Divestitures (2016 - 2017)

BeOne Medicines (ONC) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $268750.0 as the latest value for Q4 2017.

  • On a quarterly basis, Gains from Sales and Divestitures rose 504.68% to $268750.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $268750.0, a 504.68% increase, with the full-year FY2017 number at $268750.0, up 504.68% from a year prior.
  • Gains from Sales and Divestitures was $268750.0 for Q4 2017 at BeOne Medicines, up from $44445.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $533333.0 in Q4 2015 to a low of $44445.0 in Q4 2016.
  • A 3-year average of $282176.0 and a median of $268750.0 in 2017 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 91.67% in 2016, then soared 504.68% in 2017.
  • BeOne Medicines' Gains from Sales and Divestitures stood at $533333.0 in 2015, then plummeted by 91.67% to $44445.0 in 2016, then skyrocketed by 504.68% to $268750.0 in 2017.
  • Per Business Quant, the three most recent readings for ONC's Gains from Sales and Divestitures are $268750.0 (Q4 2017), $44445.0 (Q4 2016), and $533333.0 (Q4 2015).